<DOC>
	<DOCNO>NCT00932451</DOCNO>
	<brief_summary>This Phase 2 trial evaluate safety efficacy PF-02341066 patient advance non-small cell lung cancer specific gene profile involve ALK gene . This trial also allow patient Phase 3 trial receive standard care chemotherapy ( Study A8081007 ) receive PF-02341066 .</brief_summary>
	<brief_title>An Investigational Drug , PF-02341066 , Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase ( ALK ) Gene</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically cytologically proven diagnosis nonsmall cell lung cancer positive ALK fusion gene ( test provide either central laboratory . Local laboratory may use certain case ) may receive pemetrexed docetaxel previous Phase 3 trial ( A8081007 ) discontinue treatment due Response Evaluation Criterion Solid Tumors ( RECIST ) define progression . , primary endpoint Study A8081007 analyze result make available , time without RECISTdefined progression . Tumors measurable non measurable prior treatment PF02341066 receive prior systemic treatment , chemotherapy EGFR tyrosine kinase inhibitor , advance nonsmall cell lung cancer current enrollment another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lung Neoplasms ALK gene Crizotinib</keyword>
</DOC>